Ben Tran

6.4k total citations · 2 hit papers
171 papers, 2.9k citations indexed

About

Ben Tran is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Ben Tran has authored 171 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Pulmonary and Respiratory Medicine, 77 papers in Oncology and 39 papers in Surgery. Recurrent topics in Ben Tran's work include Prostate Cancer Treatment and Research (49 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Renal cell carcinoma treatment (25 papers). Ben Tran is often cited by papers focused on Prostate Cancer Treatment and Research (49 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Renal cell carcinoma treatment (25 papers). Ben Tran collaborates with scholars based in Australia, United States and United Kingdom. Ben Tran's co-authors include Philippe L. Bédard, Peter Gibbs, Jayesh Desai, Jeanne Tie, Scott Kopetz, Oliver M. Sieber, Zhi‐Qin Jiang, Christopher H. Lieu, Dipen M. Maru and Atin Agarwal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Applied and Environmental Microbiology.

In The Last Decade

Ben Tran

156 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

2011 586 citations Ben Tran, Peter Gibbs et al. profile →
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

2021 171 citations Funda Meric‐Bernstam, Rastislav Bahleda et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ben Tran Australia	26	1.6k	980	828	641	578	171	2.9k
Vicky Makker United States	34	1.9k 1.2×	953 1.0×	975 1.2×	592 0.9×	502 0.9×	180	4.6k
Steven J. Lemery United States	26	1.8k 1.1×	852 0.9×	545 0.7×	482 0.8×	627 1.1×	65	3.3k
Ullrich Graeven Germany	34	2.9k 1.8×	1.1k 1.1×	974 1.2×	781 1.2×	747 1.3×	135	4.4k
Matthew A. Powell United States	40	1.1k 0.7×	648 0.7×	1.3k 1.5×	837 1.3×	748 1.3×	182	5.7k
Joaquina Baranda United States	22	1.9k 1.2×	891 0.9×	739 0.9×	868 1.4×	440 0.8×	105	2.7k
Tommaso De Pas Italy	33	2.5k 1.6×	2.1k 2.2×	975 1.2×	417 0.7×	483 0.8×	151	4.3k
Paul DiSilvestro United States	33	2.0k 1.2×	700 0.7×	1.3k 1.6×	1.2k 1.8×	719 1.2×	159	6.4k
Jorge Barriuso United Kingdom	34	2.4k 1.5×	908 0.9×	979 1.2×	1.1k 1.6×	484 0.8×	137	4.0k
Kirsten B. Goldberg United States	39	2.7k 1.7×	1.3k 1.3×	979 1.2×	431 0.7×	349 0.6×	66	4.5k
Erika Martinelli Italy	23	2.2k 1.4×	859 0.9×	629 0.8×	595 0.9×	728 1.3×	86	3.4k

Countries citing papers authored by Ben Tran

Since Specialization

Citations

This map shows the geographic impact of Ben Tran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Tran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Tran more than expected).

Fields of papers citing papers by Ben Tran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben Tran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Tran. The network helps show where Ben Tran may publish in the future.

Co-authorship network of co-authors of Ben Tran

This figure shows the co-authorship network connecting the top 25 collaborators of Ben Tran. A scholar is included among the top collaborators of Ben Tran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ben Tran. Ben Tran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bagrodia, Aditya, et al.. (2025). Optimal Management of Stage II Seminoma: Preventing Harm While Preserving Cure. JCO Oncology Practice. 22(2). 207–215.

Ali, Muhammad, et al.. (2024). SABR for oligometastatic renal cell carcinoma. Clinical and Translational Radiation Oncology. 45. 100739–100739. 3 indexed citations

Antón, A., et al.. (2024). The value of real world evidence and pragmatic trials in advanced prostate cancer- insights from the electronic Prostate Cancer Australian and Asian Database. Frontiers in Oncology. 14. 1494073–1494073.

Tran, Ben, Mark Voskoboynik, Johanna C. Bendell, et al.. (2024). A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. Immunotherapy. 16(11). 759–774. 5 indexed citations

Marx, Gavin, Simon Chowdhury, Laurence E. Krieger, et al.. (2024). A practical guide for the use of apalutamide for non‐metastatic castration‐resistant prostate cancer in Australia. Asia-Pacific Journal of Clinical Oncology. 20(4). 435–443.

Antón, A., Natalie WH Tan, Phillip Parente, et al.. (2024). Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors. JCO Oncology Practice. 20(9). 1231–1242. 1 indexed citations

Seidel, Christoph, Elizabeth A. Connolly, Peter Grimison, et al.. (2024). Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis. ESMO Open. 9(5). 103449–103449. 2 indexed citations

Voss, Martin H., Benjamin Garmezy, J.P. Maroto Rey, et al.. (2023). 1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC). Annals of Oncology. 34. S1012–S1012. 7 indexed citations

Kelly, Richard, Christina Guo, Jayesh Desai, & Ben Tran. (2023). Changing trends in phase 1 oncology clinical trials. Contemporary Clinical Trials Communications. 37. 101239–101239. 2 indexed citations

10.

Lewin, Jeremy, Andrew Weickhardt, James Lynam, et al.. (2023). Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. JCO Oncology Practice. 19(11). 973–980. 3 indexed citations

11.

Ftanou, Maria, et al.. (2023). Malignancy, masculinities, and psychological distress: Comparisons made between men with testicular cancer and healthy controls. Psycho-Oncology. 33(1). e6262–e6262. 2 indexed citations

12.

Guo, Christina, Allan Ben Smith, Benjamin Thomas, et al.. (2022). Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study. JMIR Cancer. 8(4). e39725–e39725. 2 indexed citations

13.

Meric‐Bernstam, Funda, Rastislav Bahleda, Cinta Hierro, et al.. (2021). Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discovery. 12(2). 402–415. 171 indexed citations breakdown →

14.

Mangiola, Stefano, Geoff Macintyre, Ryan Hutchinson, et al.. (2021). MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer and Prostatic Diseases. 24(4). 1167–1180. 6 indexed citations

15.

Antón, A., Shirley Wong, Andrew Weickhardt, et al.. (2021). Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study. European Journal of Cancer. 157. 485–492. 8 indexed citations

16.

Lloyd, Paul, Anne Hong, Marc A. Furrer, et al.. (2021). A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. World Journal of Urology. 40(1). 119–126. 22 indexed citations

17.

Kwan, Edmond M., et al.. (2020). Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. European Urology Focus. 7(4). 752–763. 11 indexed citations

18.

Antón, A., Patrick Bowden, Anthony J. Costello, et al.. (2020). Use of prostate‐specific membrane antigen positron‐emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. British Journal of Urology. 126(4). 433–435. 12 indexed citations

19.

Smith, Allan Ben, Ian Olver, Peter Grimison, et al.. (2017). e-TC: Development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer. European Journal of Cancer Care. 26(6). e12698–e12698. 28 indexed citations

20.

Tran, Ben. (2009). Green Management: The Reality of Being Green in Business. Americanae (AECID Library). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact